利拉鲁肽治疗2型糖尿病的研究现状

Research Status of Liraglutide in the Treatment of Type 2 Diabetes

近些年,全球糖尿病(diabetic mellitus,DM)患病人数一直在大幅度增加,T2DM已经成为威胁人类健康的世界性公共卫生问题。而既往临床上常常通过口服双胍类、磺脲类以及α-糖苷酶抑制剂类等药物治疗此病,或者通过胰岛素类药物以达到控制血糖目的,虽然可以在一定程度上改善患者症状,延缓病情,但仍存在一定局限性。而利拉鲁肽(Liraglutide),作为GLP-1受体激动剂中的代表性药物,能有效降低患者血糖水平,控制血糖波动范围及变异幅度,显著改善胰岛β细胞功能。文章通过检索近年来国内外相关文献,对其降糖机制、临床应用以及不良反应作一综述,为临床合理用药及降糖药物开发提供参考。

In recent years,the number of patients with diabetes mellitus(DM) worldwide has been increasing significantly,and T2DM has become a worldwide public health problem threatening human health.In the past,it is often treated by oral metformin,sulfonylureas and α-glucosidase inhibitors,or insulin drugs to control blood glucose.Although it can improve the symptoms of patients and delay the disease to a certain extent,there are still some limitations.Liraglutide,as a representative drug in GLP-1 receptor agonist,can effectively reduce the blood glucose level of patients,control the range of blood glucose fluctuation and variation,and significantly improve the function of islets β cell function.This article reviews its hypoglycemic mechanism,clinical application and adverse reactions by searching the relevant literature at home and abroad in recent years,so as to to provide references basis for clinical rational drug use and hypoglycemic drug development.